Nuformix plc (LON:NFX – Get Free Report) was down 12% during trading on Wednesday. The stock traded as low as GBX 0.11 and last traded at GBX 0.11. 24,017,961 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 29,027,189 shares. The stock had previously closed at GBX 0.12.
Nuformix Stock Down 12.0%
The firm’s 50 day simple moving average is GBX 0.15 and its 200-day simple moving average is GBX 0.17. The company has a market capitalization of £2.87 million, a PE ratio of -3.75 and a beta of 1.53.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
